Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KNSA Stock Price Chart Interactive Chart >
KNSA Price/Volume Stats
| Current price | $12.19 | 52-week high | $24.70 |
| Prev. close | $11.94 | 52-week low | $11.52 |
| Day low | $11.80 | Volume | 979,200 |
| Day high | $12.50 | Avg. volume | 468,801 |
| 50-day MA | $13.15 | Dividend yield | N/A |
| 200-day MA | $16.61 | Market Cap | 835.30M |
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
Latest KNSA News From Around the Web
Below are the latest news stories about Kiniksa Pharmaceuticals Ltd that investors may wish to consider to help them evaluate KNSA as an investment opportunity.
Kiniksa Announces Launch of ARCALYST Named Patient Program- Named Patient Program supports patient access to ARCALYST® (rilonacept) in countries where ARCALYST is not currently commercially available - HAMILTON, Bermuda, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant |
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz PharmaHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, ... |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue EstimatesKiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 11.59% and 200.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity- Q2 2021 ARCALYST® (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data from mavrilimumab clinical trial in COVID-19-related ARDS on-track for Q1 2022; new Phase 2 data demonstrate persistent clinical effect through Day 90 - - Initiation of KPL-404 Phase 2 proof-of-concept clinical trial expected in Q4 2021 - - Conference call and webcast scheduled for 8:30 a.m. ET today - HAMILTON, Bermuda, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceutic |
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare ConferenceHAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 2:55 p.m. Eastern Time. |
KNSA Price Returns
| 1-mo | -0.08% |
| 3-mo | -14.70% |
| 6-mo | -28.00% |
| 1-year | -29.29% |
| 3-year | -59.05% |
| 5-year | N/A |
| YTD | -31.01% |
| 2020 | 59.76% |
| 2019 | -60.63% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...